PP
CRSP icon

PagnatoKarp Partners’s CRISPR Therapeutics CRSP Stock Holding History

PagnatoKarp Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,832
Closed -$247K – 31
2020
Q1 		$247K Buy
5,832
+2,416
+71% +$125K 0.06% 135
2019
Q4 		$208K Buy
+3,416
New +$187K 0.04% 177

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

PagnatoKarp Partners's CRSP Position: Q2 2020 in Review

PagnatoKarp Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 5,832 shares — an estimated $247K sold.

PagnatoKarp Partners first reported a position in CRSP in Q4 2019 and held it in 2 quarters. The position peaked at $247K in Q1 2020. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • PagnatoKarp Partners reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • PagnatoKarp Partners sold 5,832 CRISPR Therapeutics shares in Q2 2020, an estimated $247K.
  • PagnatoKarp Partners first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 2 quarters.
  • PagnatoKarp Partners's CRISPR Therapeutics position peaked at $247K in Q1 2020.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.